The Role of Adrenomedullin as a Predictive Marker of the Risk of Death and Adverse Clinical Events: A Review of the Literature
Abstract
:1. Introduction
2. Materials and Methods
3. Results
3.1. Role of ADM in Cardiovascular Mortality
3.2. Correlation with Mortality in COVID-19
3.3. Correlation with Clinical Worsening and Death in Sepsis
3.4. Correlation with Worsening Renal Function
3.5. Correlation with Worsening of Neoplastic Diseases and Resistance to Chemotherapy
3.6. Correlation with Clinical Worsening of Other Diseases
4. Discussion
4.1. Cardiovascular Activity
4.2. The Role in Death from Sepsis
4.3. The Role in Identifying Severe Forms of COVID-19
4.4. Physiology of ADM in the Prognosis of Renal Diseases
4.5. Function of ADM in the Prognosis of Neoplastic Diseases
4.6. Correlation with Prognosis of Other Diseases
4.7. Clinical Trials Devoted to Treatment with ADM
4.8. Therapeutic Application of ADM Antibodies
4.9. Future Perspectives
5. Conclusions
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- Kitamura, K.; Kangawa, K.; Kawamoto, M.; Ichiki, Y.; Nakamura, S.; Matsuo, H.; Eto, T. Adrenomedullin: A novel hypotensive peptide isolated from human pheochromocytoma. Biochem. Biophys. Res. Commun. 1993, 192, 553–560. [Google Scholar] [CrossRef] [PubMed]
- Ramandi, M.M.A.; Hendriks, P.M.; Voors, A.A.; Bosch, A.E.v.D.; van Melle, J.P. Bioactive adrenomedullin as a marker of congestion and disease progression in patients with a systemic right ventricle. Int. J. Cardiol. 2024, 408, 132107. [Google Scholar] [CrossRef] [PubMed]
- Fischer, J.P.; Els-Heindl, S.; Beck-Sickinger, A.G. Adrenomedullin—Current perspective on a peptide hormone with significant therapeutic potential. Peptides 2020, 131, 170347. [Google Scholar] [CrossRef] [PubMed]
- Beer, B.N.; Kellner, C.; Sundermeyer, J.; Besch, L.; Dettling, A.; Kirchhof, P.; Blankenberg, S.; Magnussen, C.; Schrage, B. Prediction of cardiac worsening through to cardiogenic shock in patients with acute heart failure. ESC Hear. Fail. 2024, 11, 2249–2258. [Google Scholar] [CrossRef] [PubMed]
- Špinarová, M.; Špinar, J.; Špinarová, L.; Krejčí, J.; Goldbergová-Pávková, M.; Pařenica, J.; Ludka, O.; Málek, F.; Ošťádal, P.; Benešová, K.; et al. Relation between Mid-Regional Pro-Adrenomedullin in Patients with Chronic Heart Failure and the Dose of Diuretics in 2-Year Follow-up-Data from FAR NHL Registry. Medicina 2022, 58, 1477. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Wallentin, L.; Eriksson, N.; Olszowka, M.; Grammer, T.B.; Hagström, E.; Held, C.; Kleber, M.E.; Koenig, W.; März, W.; Stewart, R.A.H.; et al. Plasma proteins associated with cardiovascular death in patients with chronic coronary heart disease: A retrospective study. PLOS Med. 2021, 18, e1003513. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Ahmed, A.; Kania, K.; Rahim, H.A.; Ahmed, S.; Rådegran, G. Adrenomedullin peptides and precursor levels in relation to haemodynamics and prognosis after heart transplantation. ESC Heart Fail. 2023, 10, 2427–2437. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Stanisz-Kempa, J.; Gąsior, Z.; Kułach, A. Proadrenomedullin in Patients with Preserved Left Ventricular Systolic Function Undergoing Coronary Artery Bypass Grafting. Braz. J. Cardiovasc. Surg. 2022, 37, 219–226. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Burger, A.; Stojkovic, S.; Diedrich, A.; Wojta, J.; Demyanets, S.; Pezawas, T. Cardiac biomarkers for risk stratification of arrhythmic death in patients with heart failure and reduced ejection fraction. Br. J. Biomed. Sci. 2021, 78, 195–200. [Google Scholar] [CrossRef] [PubMed]
- Bobillo-Perez, S.; Girona-Alarcon, M.; Cañizo, D.; Camprubi-Camprubi, M.; Rodriguez-Fanjul, J.; Balaguer, M.; Benito, S.; Valls, A.; Cambra, F.J.; Jordan, I. Mid-regional pro-adrenomedullin for diagnosing evolution after cardiac surgery in newborns: The PRONEW study. Eur. J. Pediatr. 2022, 181, 1017–1028. [Google Scholar] [CrossRef] [PubMed]
- Gombert, A.; Doukas, P.; Marx, G.; Hartmann, O.; Bergmann, D.; Schulte, J.; Stoppe, C.; Jacobs, M.; Simon, T. Postoperatively increased bioactive adrenomedullin is related to adverse outcome after complex aortic surgery. Vasa 2020, 49, 187–194. [Google Scholar] [CrossRef] [PubMed]
- Yuyun, M.F.; Narayan, H.K.; Quinn, P.A.; Struck, J.; Bergmann, A.; Hartmann, O.; Ng, L.L. Prognostic value of human mature adrenomedullin in patients with acute myocardial infarction. J. Cardiovasc. Med. 2017, 18, 42–50. [Google Scholar] [CrossRef] [PubMed]
- Odermatt, J.; Meili, M.; Hersberger, L.; Bolliger, R.; Christ-Crain, M.; Briel, M.; Bucher, H.C.; Mueller, B.; Schuetz, P. Pro-Adrenomedullin predicts 10-year all-cause mortality in community-dwelling patients: A prospective cohort study. BMC Cardiovasc. Disord. 2017, 17, 178. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- O′Donoghue, M.L.; Morrow, D.A.; Cannon, C.P.; Jarolim, P.; Desai, N.R.; Sherwood, M.W.; Murphy, S.A.; Gerszten, R.E.; Sabatine, M.S. Multimarker Risk Stratification in Patients with Acute Myocardial Infarction. J. Am. Heart Assoc. 2016, 5, e002586. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Spoto, S.; Argemi, J.; Di Costanzo, R.; Gomez, J.J.G.; Gonzales, N.S.; Basili, S.; Cangemi, R.; Abbate, A.; Locorriere, L.; Masini, F.; et al. Mid-Regional Pro-Adrenomedullin and N-Terminal Pro-B-Type Natriuretic Peptide Measurement: A Multimarker Approach to Diagnosis and Prognosis in Acute Heart Failure. J. Pers. Med. 2023, 13, 1155. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Self, W.H.; Storrow, A.B.; Hartmann, O.; Barrett, T.W.; Fermann, G.J.; Maisel, A.S.; Struck, J.; Bergmann, A.; Collins, S.P. Plasma bioactive adrenomedullin as a prognostic biomarker in acute heart failure. Am. J. Emerg. Med. 2016, 34, 257–262. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Sanduzzi, Z.S.; Fucci, V.; Rea, G.; Perna, F.; Bocchino, M.; Sanduzzi, Z.A. The Role of SARS-CoV-2 Nucleocapsidic Antigen and Krebs von den Lungen 6 Serum Levels in Predicting COVID-19 Pneumonia Outcome. Diagnostics 2024, 14, 642. [Google Scholar] [CrossRef] [PubMed]
- Leininger, S.B.; Staudner, S.T.; Vogel, M.J.; Mustroph, J.; Hubauer, U.; Wallner, S.; Lehn, P.; Burkhardt, R.; Meindl, C.; Hanses, F.; et al. Bioactive adrenomedullin and interleukin-6 in COVID-19: Potential biomarkers of acute kidney injury and critical illness. BMC Nephrol. 2024, 25, 52. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Montrucchio, G.; Sales, G.; Balzani, E.; Lombardo, D.; Giaccone, A.; Cantù, G.; D′Antonio, G.; Rumbolo, F.; Corcione, S.; Simonetti, U.; et al. Effectiveness of mid-regional pro-adrenomedullin, compared to other biomarkers (including lymphocyte subpopulations and immunoglobulins), as a prognostic biomarker in COVID-19 critically ill patients: New evidence from a 15-month observational prospective study. Front. Med. 2023, 10, 1122367. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Popov, D.; Borovkova, U.; Rybka, M.; Ramnyonok, T.; Golukhova, E. Mid-regional pro-adrenomedullin as a predictor of in-hospital mortality in adult patients with COVID-19: A single-centre prospective study. Anaesthesiol. Intensiv. Ther. 2022, 54, 242–246. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Sozio, E.; Tascini, C.; Fabris, M.; D’aurizio, F.; De Carlo, C.; Graziano, E.; Bassi, F.; Sbrana, F.; Ripoli, A.; Pagotto, A.; et al. MR-proADM as prognostic factor of outcome in COVID-19 patients. Sci. Rep. 2021, 11, 5121. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Indirli, R.; Bandera, A.; Valenti, L.; Ceriotti, F.; Di Modugno, A.; Tettamanti, M.; Gualtierotti, R.; Peyvandi, F.; Montano, N.; Blasi, F.; et al. COVID-19 Network Working Group. Prognostic value of copeptin and mid-regional proadrenomedullin in COVID-19-hospitalized patients. Eur. J. Clin. Investig. 2022, 52, e13753. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Zaninotto, M.; Mion, M.M.; Marchioro, L.; Padoan, A.; Plebani, M. Endothelial dysfunction and Mid-Regional proAdrenomedullin: What role in SARS-CoV-2 infected Patients? Clin. Chim. Acta 2021, 523, 185–190. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- de Guadiana-Romualdo, L.G.; Nieves, M.D.C.; Mulero, M.D.R.; Alises, I.C.; Olivo, M.H.; Fernández, W.T.; Morales, M.G.; Jiménez, C.B.; Albaladejo-Otón, M.D.; Ovalle, H.F.; et al. MR-proADM as marker of endotheliitis predicts COVID-19 severity. Eur. J. Clin. Investig. 2021, 51, e13511. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Cander, B.; Visneci, E.F.; Karaoglan, O.; Cakmak, F.; Tuncar, A.; Taslidere, B. Diagnostic and prognostic value of MR-pro ADM, procalcitonin, and copeptin in sepsis. Open Med. 2023, 18, 20230865. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Valenzuela-Sánchez, F.; Valenzuela-Méndez, B.; de Austria, R.B.; Rodríguez-Gutiérrez, J.F.; Estella-García, A.; Fernández-Ruiz, L.; González-García, M.; Rello, J. Plasma levels of mid-regional pro-adrenomedullin in sepsis are associated with risk of death. Minerva Anestesiol. 2019, 85, 366–375. [Google Scholar] [CrossRef] [PubMed]
- Charles, P.E.; Péju, E.; Dantec, A.; Bruyère, R.; Meunier-Beillard, N.; Dargent, A.; Prin, S.; Wilson, D.; Quenot, J.P. Mr-Proadm Elevation Upon Icu Admission Predicts the Outcome of Septic Patients and is Correlated with Upcoming Fluid Overload. Shock 2017, 48, 418–426. [Google Scholar] [CrossRef] [PubMed]
- Lundberg, O.H.M.; Bergenzaun, L.; Rydén, J.; Rosenqvist, M.; Melander, O.; Chew, M.S. Adrenomedullin and endothelin-1 are associated with myocardial injury and death in septic shock patients. Crit. Care 2016, 20, 178. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Mörtberg, J.; Salzinger, B.; Lundwall, K.; Edfors, R.; Jacobson, S.H.; Wallén, H.N.; Jernberg, T.; Baron, T.; Erlinge, D.; Andell, P.; et al. Prognostic importance of biomarkers associated with haemostatic, vascular and endothelial disturbances in acute coronary syndrome patients in relation to kidney function. Int. J. Cardiol. 2023, 373, 64–71. [Google Scholar] [CrossRef] [PubMed]
- Edfors, R.; Lindhagen, L.; Spaak, J.; Evans, M.; Andell, P.; Baron, T.; Mörtberg, J.; Rezeli, M.; Salzinger, B.; Lundman, P.; et al. Use of proteomics to identify biomarkers associated with chronic kidney disease and long-term outcomes in patients with myocardial infarction. J. Intern. Med. 2020, 288, 581–592. [Google Scholar] [CrossRef] [PubMed]
- Kakareko, K.; Rydzewska-Rosołowska, A.; Rygasiewicz, K.; Siemiątkowski, A.; Koc-Żórawska, E.; Zbroch, E.; Hryszko, T. Prognostic value of mid-regional proadrenomedullin in critically ill patients. Pol. Arch. Intern. Med. 2019, 129, 673–678. [Google Scholar] [CrossRef] [PubMed]
- Uetake, R.; Sakurai, T.; Kamiyoshi, A.; Ichikawa-Shindo, Y.; Kawate, H.; Iesato, Y.; Yoshizawa, T.; Koyama, T.; Yang, L.; Toriyama, Y.; et al. Adrenomedullin-RAMP2 system suppresses ER stress-induced tubule cell death and is involved in kidney protection. PLoS ONE 2014, 9, e87667. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Artunc, F.; Nowak, A.; Mueller, C.; Breidthardt, T.; Twerenbold, R.; Wagner, R.; Peter, A.; Haering, H.-U.; Ebmeyer, S.; Friedrich, B. Plasma concentrations of the vasoactive peptide fragments mid-regional pro-adrenomedullin, C-terminal pro-endothelin 1 and copeptin in hemodialysis patients: Associated factors and prediction of mortality. PLoS ONE 2014, 9, e86148. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Maier, C.; Clodi, M.; Neuhold, S.; Resl, M.; Elhenicky, M.; Prager, R.; Moertl, D.; Strunk, G.; Luger, A.; Struck, J.; et al. Endothelial markers may link kidney function to cardiovascular events in type 2 diabetes. Diabetes Care 2009, 32, 1890–1895. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Dai, X.; Ma, W.; He, X.J.; Jha, R.K. Elevated expression of adrenomedullin is correlated with prognosis and disease severity in osteosarcoma. Med. Oncol. 2013, 30, 347. [Google Scholar] [CrossRef] [PubMed]
- Hollander, L.L.; Guo, X.; Salem, R.R.; Cha, C.H. The novel tumor angiogenic factor, adrenomedullin-2, predicts survival in pancreatic adenocarcinoma. J. Surg. Res. 2015, 197, 219–224. [Google Scholar] [CrossRef] [PubMed]
- Warrington, J.I.; Richards, G.O.; Wang, N. The Role of the Calcitonin Peptide Family in Prostate Cancer and Bone Metastasis. Curr. Mol. Biol. Rep. 2017, 3, 197–203. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Qiao, F.; Fang, J.; Xu, J.; Zhao, W.; Ni, Y.; Akuo, B.A.; Zhang, W.; Liu, Y.; Ding, F.; Li, G.; et al. The role of adrenomedullin in the pathogenesis of gastric cancer. Oncotarget 2017, 8, 88464–88474. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Liu, L.L.; Chen, S.L.; Huang, Y.H.; Yang, X.; Wang, C.H.; He, J.H.; Yun, J.P.; Luo, R.Z. Adrenomedullin inhibits tumor metastasis and is associated with good prognosis in triple-negative breast cancer patients. Am. J. Transl. Res. 2020, 12, 773–786. [Google Scholar] [PubMed] [PubMed Central]
- Maia, L.L.; Peterle, G.T.; Dos Santos, M.; Trivilin, L.O.; Mendes, S.O.; de Oliveira, M.M.; Dos Santos, J.G.; Stur, E.; Agostini, L.P.; Couto, C.V.M.D.S.; et al. JMJD1A, H3K9me1, H3K9me2 and ADM expression as prognostic markers in oral and oropharyngeal squamous cell carcinoma. PLoS ONE 2018, 13, e0194884. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Wang, X.; Jia, J.; Zhang, M.; Meng, Q.; Yan, B.; Ma, Z.; Wang, D. Adrenomedullin/FOXO3 enhances sunitinib resistance in clear cell renal cell carcinoma by inhibiting FDX1 expression and cuproptosis. FASEB J. 2023, 37, e23143. [Google Scholar] [CrossRef] [PubMed]
- Yoshizawa, T.; Takizawa, S.; Shimada, S.; Tokudome, T.; Shindo, T.; Matsumoto, K. Effects of Adrenomedullin on Doxorubicin-Induced Cardiac Damage in Mice. Biol. Pharm. Bull. 2016, 39, 737–746. [Google Scholar] [CrossRef] [PubMed]
- Ramirez, M.F.; Honigberg, M.; Wang, D.; Parekh, J.K.; Bielawski, K.; Courchesne, P.; Larson, M.D.; Levy, D.; Murabito, J.M.; Ho, J.E.; et al. Protein Biomarkers of Early Menopause and Incident Cardiovascular Disease. J. Am. Heart Assoc. 2023, 12, e028849. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Brandão, M.; Fonseca, T.; Costa, R.Q.; Oliveira, J.C.; Carvalho, H.C.; Rodrigues, P.; Zannad, F.; Rossignol, P.; Ferreira, M.B.; Ferreira, J.P. Impact of disease duration on proteomic bioprofile and prognosis in rheumatoid arthritis patients. Clin. Exp. Rheumatol. 2023, 41, 2162–2166. [Google Scholar] [CrossRef] [PubMed]
- Emmez, G.; Bulduk, E.B.; Yıldırım, Z. Neuroprotective effects of adrenomedullin in experimental traumatic brain injury model in rats. Turk. J. Trauma Emerg. Surg. 2022, 28, 736–742. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Ihara, M.; Washida, K.; Yoshimoto, T.; Saito, S. Adrenomedullin: A vasoactive agent for sporadic and hereditary vascular cognitive impairment. Cereb. Circ. Cogn. Behav. 2021, 2, 100007. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Mahmoodazdeh, A.; Shafiee, S.M.; Sisakht, M.; Khoshdel, Z.; Takhshid, M.A. Adrenomedullin protects rat dorsal root ganglion neurons against doxorubicin-induced toxicity by ameliorating oxidative stress. Iran. J. Basic Med. Sci. 2020, 23, 1197–1206. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Zuur-Telgen, M.C.; Citgez, E.; Zuur, A.T.; VanderValk, P.; van der Palen, J.; Kerstjens, H.A.M.; Brusse-Keizer, M. Predicting Mortality in COPD with Validated and Sensitive Biomarkers; Fibrinogen and Mid-Range-Proadrenomedullin (MR-proADM). COPD J. Chronic Obstr. Pulm. Dis. 2021, 18, 643–649. [Google Scholar] [CrossRef] [PubMed]
- Hotter, B.; Hoffmann, S.; Ulm, L.; Montaner, J.; Bustamante, A.; Meisel, C.; Meisel, A. Inflammatory and stress markers predicting pneumonia, outcome, and etiology in patients with stroke: Biomarkers for predicting pneumonia, functional outcome, and death after stroke. Neurol. Neuroimmunol. Neuroinflammation 2020, 7, e692. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Kong, H.; You, N.; Chen, H.; Teng, Y.S.; Liu, Y.G.; Lv, Y.P.; Mao, F.Y.; Cheng, P.; Chen, W.; Zhao, Z.; et al. Helicobacter pylori-induced adrenomedullin modulates IFN-γ-producing T-cell responses and contributes to gastritis. Cell Death Dis. 2020, 11, 189. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Kato, J.; Tsuruda, T.; Kita, T.; Kitamura, K.; Eto, T. Adrenomedullin: A protective factor for blood vessels. Arter. Thromb. Vasc. Biol. 2005, 25, 2480–2487. [Google Scholar] [CrossRef] [PubMed]
- Jacob, A.; Wang, Z.; Yen, H.T.; Wang, P. Human adrenomedullin and its binding protein attenuate tissue injury and inflammation following hepatic ischemia reperfusion in rabbits. Heliyon 2021, 7, e07845. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Frydland, M.; E Møller, J.; Lindholm, M.G.; Hansen, R.; Wiberg, S.; Helgestad, O.K.L.; Thomsen, J.H.; Goetze, J.P.; Engstrøm, T.; Frikke-Schmidt, R.; et al. Biomarkers predictive of late cardiogenic shock development in patients with suspected ST-elevation myocardial infarction. Eur. Heart J. Acute Cardiovasc. Care 2020, 9, 557–566. [Google Scholar] [CrossRef] [PubMed]
- Zeng, Q.; Lin, Q.; Zhong, L.; He, L.; Zhang, N.; Song, J. Development and validation of a nomogram to predict mortality of patients with DIC in ICU. Front. Med. 2024, 11, 1425799. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- de Guadiana-Romualdo, L.G.; Botella, L.A.; Rojas, C.R.; Candel, A.P.; Sánchez, R.J.; Zamora, P.C.; Albaladejo-Otón, M.D.; Allegue-Gallego, J.M.; de Guadiana-Romualdo, L.G.; Botella, L.A.; et al. Mortality prediction model from combined serial lactate, procalcitonin and calprotectin levels in critically ill patients with sepsis: A retrospective study according to Sepsis-3 definition. Med. Intensiv. 2024, S2173-5727(24)00138-3. [Google Scholar] [CrossRef] [PubMed]
- Nishikimi, T. Adrenomedullin in the kidney-renal physiological and pathophysiological roles. Curr. Med. Chem. 2007, 14, 1689–1699. [Google Scholar] [CrossRef] [PubMed]
- Jailani, A.B.A.; Bigos, K.J.A.; Avgoustou, P.; Egan, J.L.; Hathway, R.A.; Skerry, T.M.; Richards, G.O. Targeting the adrenomedullin-2 receptor for the discovery and development of novel anti-cancer agents. Expert Opin. Drug Discov. 2022, 17, 839–848. [Google Scholar] [CrossRef] [PubMed]
- Bálint, L.; Nelson-Maney, N.P.; Tian, Y.; Serafin, S.D.; Caron, K.M. Clinical Potential of Adrenomedullin Signaling in the Cardiovascular System. Circ. Res. 2023, 132, 1185–1202. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Washida, K.; Saito, S.; Tanaka, T.; Nakaoku, Y.; Ishiyama, H.; Abe, S.; Kuroda, T.; Nakazawa, S.; Kakuta, C.; Omae, K.; et al. A multicenter, single-arm, phase II clinical trial of adrenomedullin in patients with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Cereb. Circ. Cogn. Behav. 2024, 6, 100211. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Kita, T.; Kitamura, K. Translational studies of adrenomedullin and related peptides regarding cardiovascular diseases. Hypertens. Res. 2022, 45, 389–400. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Geven, C.; Kox, M.; Pickkers, P. Adrenomedullin and Adrenomedullin-Targeted Therapy as Treatment Strategies Relevant for Sepsis. Front. Immunol. 2018, 9, 292. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Ashizuka, S.; Kita, T.; Inatsu, H.; Kitamura, K. Adrenomedullin: A Novel Therapeutic for the Treatment of Inflammatory Bowel Disease. Biomedicines 2021, 9, 1068. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Struck, J.; Hein, F.; Karasch, S.; Bergmann, A. Epitope specificity of anti-Adrenomedullin antibodies determines efficacy of mortality reduction in a cecal ligation and puncture mouse model. Intensiv. Care Med. Exp. 2013, 1, 3. [Google Scholar] [CrossRef] [PubMed]
- Blet, A.; Deniau, B.; Geven, C.; Sadoune, M.; Caillard, A.; Kounde, P.-R.; Polidano, E.; Pickkers, P.; Samuel, J.L.; Mebazaa, A. Adrecizumab, a non-neutralizing anti-adrenomedullin antibody, improves haemodynamics and attenuates myocardial oxidative stress in septic rats. Intensiv. Care Med. Exp. 2019, 7, 25. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Geven, C.; Blet, A.; Kox, M.; Hartmann, O.; Scigalla, P.; Zimmermann, J.; Marx, G.; Laterre, P.-F.; Mebazaa, A.; Pickkers, P. A double-blind, placebo-controlled, randomised, multicentre, proof-of-concept and dose-finding phase II clinical trial to investigate the safety, tolerability and efficacy of adrecizumab in patients with septic shock and elevated adrenomedullin concentration (AdrenOSS-2). BMJ Open 2019, 9, e024475. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Benyahia, Z.; Gaudy-Marqueste, C.; Berenguer-Daizé, C.; Chabane, N.; Dussault, N.; Cayol, M.; Vellutini, C.; Djemli, A.; Nanni, I.; Beaufils, N.; et al. Adrenomedullin Secreted by Melanoma Cells Promotes Melanoma Tumor Growth through Angiogenesis and Lymphangiogenesis. Cancers 2022, 14, 5909. [Google Scholar] [CrossRef] [PubMed]
- Vázquez, R.; Riveiro, M.E.; Berenguer-Daizé, C.; O′kane, A.; Gormley, J.; Touzelet, O.; Rezai, K.; Bekradda, M.; Ouafik, L. Targeting Adrenomedullin in Oncology: A Feasible Strategy with Potential as Much More Than an Alternative Anti-Angiogenic Therapy. Front. Oncol. 2021, 10, 589218. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Kita, T.; Ashizuka, S.; Takeda, T.; Matsumoto, T.; Ohmiya, N.; Nakase, H.; Motoya, S.; Ohi, H.; Mitsuyama, K.; Hisamatsu, T.; et al. Adrenomedullin for biologic-resistant Crohn’s disease: A randomized, double-blind, placebo-controlled phase 2a clinical trial. J. Gastroenterol. Hepatol. 2022, 37, 2051–2059. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Laterre, P.-F.; Pickkers, P.; Marx, G.; Wittebole, X.; Meziani, F.; Dugernier, T.; Huberlant, V.; Schuerholz, T.; François, B.; Lascarrou, J.-B.; et al. Safety and tolerability of non-neutralizing adrenomedullin antibody adrecizumab (HAM8101) in septic shock patients: The AdrenOSS-2 phase 2a biomarker-guided trial. Intensiv. Care Med. 2021, 47, 1284–1294. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
Associated Marker | Prognostic Value |
---|---|
NT-proBNP | Hospitalization in heart failure |
CRP | Severity of COVID-19 |
Procalcitonin | Clinical evolution of sepsis |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Sacco, M.A.; Gualtieri, S.; Cordasco, F.; Tarallo, A.P.; Verrina, M.C.; Princi, A.; Bruni, A.; Garofalo, E.; Aquila, I. The Role of Adrenomedullin as a Predictive Marker of the Risk of Death and Adverse Clinical Events: A Review of the Literature. J. Clin. Med. 2024, 13, 4847. https://doi.org/10.3390/jcm13164847
Sacco MA, Gualtieri S, Cordasco F, Tarallo AP, Verrina MC, Princi A, Bruni A, Garofalo E, Aquila I. The Role of Adrenomedullin as a Predictive Marker of the Risk of Death and Adverse Clinical Events: A Review of the Literature. Journal of Clinical Medicine. 2024; 13(16):4847. https://doi.org/10.3390/jcm13164847
Chicago/Turabian StyleSacco, Matteo Antonio, Saverio Gualtieri, Fabrizio Cordasco, Alessandro Pasquale Tarallo, Maria Cristina Verrina, Aurora Princi, Andrea Bruni, Eugenio Garofalo, and Isabella Aquila. 2024. "The Role of Adrenomedullin as a Predictive Marker of the Risk of Death and Adverse Clinical Events: A Review of the Literature" Journal of Clinical Medicine 13, no. 16: 4847. https://doi.org/10.3390/jcm13164847